As of April 16, 2025, Cullinan Therapeutics (CGEM) has a market cap of $0.46 billion USD. According to our data, Cullinan Therapeutics is ranked No.6068 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $0.46 B |
-35.65%
|
Dec 31, 2024 | $0.71 B |
19.53%
|
Dec 29, 2023 | $0.59 B |
-3.41%
|
Dec 30, 2022 | $0.61 B |
-31.63%
|
Dec 31, 2021 | $0.90 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$286.98 B |
70.023 B
|
![]() Denmark
|
![]() Novo Nordisk A/S
NOVO-B.CO
|
$283.41 B |
66.691 B
|
![]() Denmark
|
![]() Roche
ROG.SW
|
$246.83 B |
32.151 B
|
![]() Switzerland
|
![]() Novartis
NVS
|
$217.12 B |
0.003 M
|
![]() Switzerland
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Thermo Fisher Scientific
TMO
|
$166.47 B |
0.002 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
![]() USA
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() CVS Health
CVS
|
$87.00 B |
-0.003 M
|
![]() USA
|
![]() Chugai Pharmaceutical
4519.T
|
$77.71 B |
1.323 B
|
![]() Japan
|
![]() CSL
CSL.AX
|
$74.32 B |
-0.679 B
|
![]() Australia
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
Market Cap | = | CGEM Stock Price | * | CGEM Shares Outstanding |
= | $7.80 | * | 58.51 M | |
= | $0.46 B |